Ionis Pharmaceuticals (NASDAQ:IONS) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research report report published on Friday morning, Benzinga reports. Needham & Company LLC currently has a $60.00 price objective on the stock. IONS has been the subject of a number of other research reports. Morgan Stanley […]

Leave a Reply

Your email address will not be published.

Previous post JPMorgan Chase & Co. Raises Applied Materials (NASDAQ:AMAT) Price Target to $170.00
Next post Wedbush Reiterates Outperform Rating for Karuna Therapeutics (NASDAQ:KRTX)